Viking Therapeutics Q3 2026 loss widens to $183M
The oral and injectable VK2735 programs are in Phase 3, with daily tablet and weekly injection regimens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Viking Therapeutics, Inc. reported third-quarter 2026 financial results, including a net loss of $183.2 million, compared with $90.8 million a year earlier. Research and development expenses were $166.8 million and general and administrative expenses were $20.3 million, both higher than in the prior-year quarter. Cash, cash equivalents and short-term investments totaled $960 million at September 30, 2026, versus $706 million at December 31, 2025. Concurrent public offerings of common stock and convertible senior notes in September generated approximately $575 million in gross proceeds.
The subcutaneous VANQUISH trials continued, and Viking initiated the oral SUNRISE Phase 3 trials for VK2735; VANQUISH completion is expected in 2027. VANQUISH tests weekly injections over 78 weeks, while SUNRISE tests daily tablets over 68 weeks. In Part 1 of a maintenance study, mean weight loss retained at Week 33 was 83%–97% with every-other-week dosing and 82%–90% with monthly dosing. Part 2 began, with results expected in 2027. Viking expected to complete VK3019’s Phase 1 single-ascending-dose study later in the quarter and initiate a 4-week multiple-ascending-dose study in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss reached $183.2 million, compared with $90.8 million a year earlier.
Filing Explained
Quarter-end figures show a higher common-share count.
The furnished third-quarter balance sheet reports 127,521,229 common shares issued and outstanding at
8-K Event Classification
Key Figures
Key Terms
GLP-1 receptor technical
GIP receptor technical
pharmacokinetic (PK) profile technical
single ascending dose (SAD) technical
convertible senior notes financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was VKTX’s net loss in the third quarter of 2026?
How much cash did VKTX have at the end of the third quarter?
What doses are being studied in VKTX’s SUNRISE trials?
How many patients enrolled in VKTX’s VANQUISH trials?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 28, 2026, we issued a press release reporting our financial results for the third quarter ended September 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No |
|
Description |
99.1
|
|
Press release issued October 28, 2026, reporting financial results for the third quarter ended September 30, 2026 and providing a corporate update. |
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Viking Therapeutics, Inc. |
|
|
|
|
Date: |
October 28, 2026 |
By: |
/s/ Brian Lian, Ph.D. |
|
|
|
President and Chief Executive Officer |
Exhibit 99.1
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance --
-- SUNRISE Phase 3 Trials for Oral VK2735 Initiated --
-- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated --
-- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion --
-- Strong Quarter-End Cash Position of $960 Million --
Conference call scheduled for 4:30 p.m. ET today
SAN DIEGO, October 28, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and other corporate developments.
Highlights from the Third Quarter Ended September 30, 2026, and Other Recent Events:
“During the third quarter, Viking continued to advance and expand development activities in its obesity franchise. We recently announced the initiation of the SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing the third and fourth registration trials to be underway. The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation and we are excited to have these important clinical trials underway. In the third quarter we also announced positive results from our initial VK2735 dose-ranging maintenance study. These results demonstrated an impressive maintenance effect, excellent tolerability, and serve to further establish VK2735 as a differentiated potential treatment option for patients with obesity. Following the successful initial readout, we announced another milestone with the initiation of Part 2 of the maintenance study. As with Part 1, subjects will transition from a weekly induction period to a range of VK2735 maintenance options
including daily oral doses, every-other-week subcutaneous doses, monthly subcutaneous doses, or placebo. The potential availability of both a tablet and a subcutaneous formulation, across a variety of dosing regimens, will offer unmatched optionality and flexibility to best support a personalized and sustainable weight loss journey. Also, during the quarter, the Phase 1 study of our dual amylin and calcitonin receptor agonist VK3019 continued to advance. Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027. To support our robust pipeline, as well as the activities related to the potential commercial launch of VK2735, during the quarter the company successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in a strong quarter-end cash balance of $960 million. This provides the company with the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy.”
Pipeline and Recent Corporate Highlights
Based on the positive findings from the Phase 2 VENTURE study, and subsequent feedback from the U.S. Food and Drug Administration (FDA), the company advanced the subcutaneous formulation of VK2735 into Phase 3 development, initiating the VANQUISH Phase 3 registration program in June of last year. The VANQUISH program consists of two clinical trials: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation. The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation. Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.
The primary endpoint of the VANQUISH trials is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve at least 5%, 10%, 15% and 20% weight loss. Each study will include an extension portion allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period, including patients who were randomized to placebo for the initial 78-week treatment period.
During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.
As with the company’s subcutaneous studies to date, the Phase 1 and Phase 2 trials of Viking’s oral tablet formulation of VK2735 successfully achieved their primary and secondary objectives. The Phase 2 VENTURE Oral Dosing study of VK2735 evaluated once daily doses of the tablet formulation. Top-line results demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 12.2% from baseline. Up to 80% of subjects in VK2735 treatment groups achieved at least 10% weight loss after 13 weeks, compared with only 5% of placebo treated subjects. The tablet formulation also demonstrated encouraging safety and tolerability through 13 weeks of daily dosing. The vast majority of drug-related treatment-emergent adverse events were characterized as mild or moderate, with no meaningful difference in gastrointestinal (GI)-related adverse events between subjects treated with VK2735 and placebo.
Earlier this month, the company announced the initiation of the SUNRISE Phase 3 registration program evaluating oral VK2735. The SUNRISE program includes two studies: SUNRISE-1 in adults with obesity and SUNRISE-2 in obese or overweight adults with type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of oral VK2735, with patients receiving once-daily doses for 68 weeks. SUNRISE-1 and SUNRISE-2 are each targeting enrollment of 560 adults. Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.
Viking is very pleased to have these important trials underway, as it believes oral VK2735 may represent another differentiated and high value treatment option for patients and physicians alike.
In the third quarter the company reported positive results from Part 1 of a two-part range-finding study. This study, which was designed to explore a variety of maintenance dosing regimens, demonstrated VK2735’s ability not only to achieve significant weight loss during the induction phase, but to also maintain a high percentage of the initial weight loss long-term using lower and less frequent dosing regimens.
Part 1 of the maintenance study was focused on subcutaneous dosing. The novel design incorporated multiple parts – a 21-week induction period, a 12-week maintenance period evaluating monthly or every-other-week dosing, and a 33-week dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were randomized across 11 treatment groups. Subjects were required to have a BMI ≥30 kg/m2 but no other comorbidities. Induction doses ranged from 15.0 mg to 22.5 mg per week, or placebo, administered once weekly by subcutaneous injection for 21 weeks. Following the 21-week induction period, subjects were transitioned to a range of subcutaneous maintenance regimens, or placebo, for an additional 12 weeks.
Through the initial 21 weeks of weekly dosing, robust weight loss was observed at all dose levels, with no signs of plateau. Week 21 weight loss ranged from approximately 16% to approximately 19% compared with approximately 0% for placebo. All doses clearly separated from placebo starting at Week 4, with p-values at each dosing level less than 0.0001 compared with placebo. Among treated subjects, 98% achieved 5% weight loss, 90% achieved 10%, 65% achieved 15%, and 32% achieved 20% weight loss. This compares well with the placebo cohort, for which only 13% achieved 5% weight loss and none achieved 10%, 15% or 20% weight loss at Week 21. Based on the weight loss trajectories among VK2735-treated subjects at Week 21, the company believes that further weight loss is likely to be observed with continued dosing.
Following the 21-week induction phase of the study, subjects were transitioned from weekly dosing to every-other-week or monthly dosing for an additional 12 weeks. Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo. Among subjects transitioned to monthly dosing, mean weight loss retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with p-values less than 0.01 for each cohort vs. placebo. The significant reduction in weight rebound compared with placebo under either regimen demonstrated a compelling maintenance signal, supporting the concept of less frequent dosing as a potentially viable regimen for long-term weight management.
The maintenance study also incorporated an exploratory cohort where subjects were maintained on a 17.5 mg weekly dose for the entire 33-week treatment window. These participants demonstrated continued weight loss throughout the 33 week study period, reaching approximately 22% from baseline. No plateau was observed, suggesting further weight loss might be expected with continued dosing.
This study also demonstrated a favorable tolerability profile and low rate of discontinuations. During the 21 week induction period, common GI adverse events such as nausea, vomiting, diarrhea, and constipation were consistent with those observed in the company’s prior Phase 2 VENTURE study. This is of particular interest as these subjects were titrated faster (every two weeks) compared with the slower titration schedule (every three weeks) used in the VENTURE study.
During the maintenance period of this study, following the transition to every-other-week or monthly dosing, an encouraging tolerability profile was also observed. Treatment emergent adverse events were similar to placebo, and GI-related adverse events were low and generally no different from placebo. These data suggest that despite a gap of up to four weeks between doses, these participants did not resensitize to GI adverse events such as nausea or vomiting. This supports the company’s view that VK2735’s differentiated PK profile, with an extended half-life and excellent long-term exposures, may provide for greater flexibility in dosing compared with existing options.
The company believes these results demonstrated a credible maintenance effect, a key objective of the study. Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027.
Following the successful completion of the first part of the maintenance dosing study, the company recently initiated Part 2 of this study, designed to evaluate a range of oral maintenance regimens, along with select subcutaneous maintenance doses. Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1, all
participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.
The company expects the results from Part 2 of this study to be available in 2027.
During the second quarter, the company initiated a Phase 1 single ascending dose (SAD) clinical trial evaluating VK3019. The Phase 1 trial is a randomized, double-blind, placebo-controlled SAD study in healthy adults with BMI ≥27. The primary objectives of the study include an evaluation of the safety, tolerability, and pharmacokinetics of VK3019 following administration of single subcutaneous doses. Exploratory pharmacodynamic assessments include evaluations of changes in body weight after a single-dose administration.
The company expects to complete the SAD study later this quarter and initiate a 4 week multiple ascending dose (MAD) study of VK3019 in 1Q27.
The addition of VK3019 to Viking’s clinical pipeline represents an important expansion of the company’s obesity franchise and further illustrates Viking’s commitment to treating obesity first with the goal of helping patients achieve and maintain a weight that will allow them to improve their overall health and quality of life.
Viking plans to make the following presentations at scientific conferences in the fourth quarter:
ObesityWeek; November 14 – 17, 2026 - Washington, D.C:
Saturday, November 14,2026, 7:30 pm - 8:30 pm ET
Poster presentation
Sunday, November 15, 2026, 2:30 pm - 3:30 pm ET
Poster presentation
Viking management will participate in the following upcoming investor events:
New York, NY
November 10 - 12, 2026
New York, NY
November 12, 2026
London, UK
November 16 - 17, 2026
London, UK
November 16 - 19, 2026
New York, NY
December 1 – 3, 2026
San Francisco, CA
January 11 – 14, 2027
Third Quarter and Nine Months 2026 Financial Highlights
Third Quarter ended September 30, 2026, and 2025
Research and development expenses were $166.8 million for the three months ended September 30, 2026, compared to $90.0 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, manufacturing for the company’s drug candidates, stock-based compensation, salaries and benefits and third-party consultants, partially offset by decreased expenses related to preclinical studies.
General and administrative expenses were $20.3 million for the three months ended September 30, 2026, compared to $8.6 million for the same period in 2025. The increase was primarily due to increased expenses related to legal and patent services, third-party consultants, stock-based compensation, and salaries and benefits. These increases reflect the company’s rapid overall growth compared with the same period in 2025.
For the three months ended September 30, 2026, Viking reported a net loss of $183.2 million, or $1.55 per share, compared to a net loss of $90.8 million, or $0.81 per share, in the corresponding period in 2025. The increase in net loss for the three months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025.
Nine Months ended September 30, 2026, and 2025
Research and development expenses were $432.7 million for the nine months ended September 30, 2026, compared to $191.5 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, stock-based compensation, manufacturing for the company’s drug candidates, salaries and benefits, and third-party consultants, partially offset by decreased expenses related to preclinical studies.
General and administrative expenses were $51.1 million for the nine months ended September 30, 2026, compared to $37.1 million for the same period in 2025. The increase was primarily due to increased expenses related to third-party consultants, legal and patent services, and salaries and benefits, partially offset by decreased expenses related to stock-based compensation. These increases reflect the company’s rapid overall growth compared with the same period in 2025.
For the nine months ended September 30, 2026, Viking reported a net loss of $469.5 million, or $4.03 per share, compared to a net loss of $202.0 million, or $1.80 per share, in the corresponding period in 2025. The increase in net loss for the nine months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025.
Balance Sheet as of September 30, 2026
At September 30, 2026, Viking held cash, cash equivalents, and short-term investments of $960 million, compared to $706 million as of December 31, 2025. This balance includes the aggregate net proceeds of approximately $550 million from the company’s recent financing.
Conference Call
Management will host a conference call to discuss Viking's third quarter 2026 financial results today at 4:30 pm Eastern. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 4, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 1882451. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at https://ir.vikingtherapeutics.com/webcasts-presentations. An archive of the webcast will also be available on the Webcasts page of Viking's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product
candidate development activities and clinical trials, including those for VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.
Viking Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenues |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
166,804 |
|
|
|
89,953 |
|
|
|
432,708 |
|
|
|
191,496 |
|
General and administrative |
|
|
20,308 |
|
|
|
8,608 |
|
|
|
51,126 |
|
|
|
37,108 |
|
Total operating expenses |
|
|
187,112 |
|
|
|
98,561 |
|
|
|
483,834 |
|
|
|
228,604 |
|
Loss from operations |
|
|
(187,112 |
) |
|
|
(98,561 |
) |
|
|
(483,834 |
) |
|
|
(228,604 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of financing costs |
|
|
— |
|
|
|
(8 |
) |
|
|
— |
|
|
|
(56 |
) |
Interest income, net |
|
|
4,014 |
|
|
|
7,772 |
|
|
|
14,359 |
|
|
|
26,669 |
|
Interest expense, net |
|
|
(88 |
) |
|
|
— |
|
|
|
(88 |
) |
|
|
— |
|
Realized gain on investments |
|
|
— |
|
|
|
10 |
|
|
|
30 |
|
|
|
14 |
|
Total other income, net |
|
|
3,926 |
|
|
|
7,774 |
|
|
|
14,301 |
|
|
|
26,627 |
|
Net loss |
|
|
(183,186 |
) |
|
|
(90,787 |
) |
|
|
(469,533 |
) |
|
|
(201,977 |
) |
Other comprehensive loss, net of tax: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized (loss) gain on investments |
|
|
(518 |
) |
|
|
540 |
|
|
|
(2,067 |
) |
|
|
1,129 |
|
Foreign currency translation (loss) gain |
|
|
(27 |
) |
|
|
— |
|
|
|
(9 |
) |
|
|
33 |
|
Comprehensive loss |
|
$ |
(183,731 |
) |
|
$ |
(90,247 |
) |
|
$ |
(471,609 |
) |
|
$ |
(200,815 |
) |
Basic and diluted net loss per share |
|
$ |
(1.55 |
) |
|
$ |
(0.81 |
) |
|
$ |
(4.03 |
) |
|
$ |
(1.80 |
) |
Weighted-average shares used to compute basic |
|
|
118,050 |
|
|
|
112,320 |
|
|
|
116,636 |
|
|
|
112,217 |
|
Viking Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|
|
September 30, |
|
|
December 31, |
|
||||
|
|
(Unaudited) |
|
|
|
|
||||
Assets |
|
|
|
|
|
|
||||
Current assets: |
|
|
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
677,609 |
|
|
$ |
165,810 |
|
||
Short-term investments – available-for-sale |
|
|
282,204 |
|
|
|
539,929 |
|
||
Prepaid clinical trial and preclinical study costs |
|
|
10,008 |
|
|
|
8,053 |
|
||
Prepaid expenses and other current assets |
|
|
3,178 |
|
|
|
1,806 |
|
||
Total current assets |
|
|
972,999 |
|
|
|
715,598 |
|
||
Right-of-use assets |
|
|
3,853 |
|
|
|
85 |
|
||
Restricted cash |
|
|
202 |
|
|
|
— |
|
||
Deposits |
|
|
113 |
|
|
|
46 |
|
||
Total assets |
|
$ |
977,167 |
|
|
$ |
715,729 |
|
||
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||||
Current liabilities: |
|
|
|
|
|
|
||||
Accounts payable |
|
$ |
82,134 |
|
|
$ |
53,251 |
|
||
Other accrued liabilities |
|
|
51,739 |
|
|
|
23,279 |
|
||
Lease liability, current |
|
|
24 |
|
|
|
137 |
|
||
Total current liabilities |
|
|
133,897 |
|
|
|
76,667 |
|
||
Lease liability, net of current portion |
|
|
4,014 |
|
|
|
— |
|
||
Convertible Notes |
|
|
250,656 |
|
|
|
— |
|
||
Total long-term liabilities |
|
|
254,670 |
|
|
|
— |
|
||
Total liabilities |
|
|
388,567 |
|
|
|
76,667 |
|
||
Commitments and contingencies |
|
|
|
|
|
|
||||
Stockholders’ equity: |
|
|
|
|
|
|
||||
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 |
|
|
— |
|
|
|
— |
|
||
Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2026 and December 31, 2025; 127,521,229 shares issued and outstanding at September 30, 2026 and 114,793,067 shares issued and outstanding at December 31, 2025 |
|
|
1 |
|
|
|
1 |
|
||
Additional paid-in capital |
|
|
1,907,376 |
|
|
|
1,486,229 |
|
||
Accumulated deficit |
|
|
(1,317,079 |
) |
|
|
(847,546 |
) |
||
Accumulated other comprehensive (loss) gain |
|
|
(1,698 |
) |
|
|
378 |
|
||
Total stockholders’ equity |
|
|
588,600 |
|
|
|
639,062 |
|
||
Total liabilities and stockholders’ equity |
|
$ |
977,167 |
|
|
$ |
715,729 |
|
||
Contacts:
Viking Therapeutics
Greg Zante
Chief Financial Officer
858-704-4672
gzante@vikingtherapeutics.com
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com